|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, November 21, 2008 ) DALLAS, Texas - BeaconEquity.com announces the publication of “Benda Pharmaceutical Reports Q3 2008 Financial Results.”
Investors can view all of the investment articles for free by visiting: http://www.beaconequity.com/m - Click on News and Commentary
In the article the author writes:
"Benda Pharmaceuticals Inc. (OTCBB: BPMA), maker of the gene therapy cancer drug Gendicine and other traditional pharmaceuticals, today announced its financial results for the third quarter and nine months ended September 30, 2008. … The China-based pharmaceutical posted revenue of $6.6 million for the third quarter of 2008, or a decrease of 12.2%, compared with $7.6 million for the same quarter of 2007.”
Benda points to its reorganization of personnel for the fall in third-quarter revenue:
“The company cites its reorganization of personnel at its SiBiono facility for the drop in revenue for the quarter. However, SiBiono has since recommenced production and resumed sales of its pharmaceutical products, the company said. Benda sold 3,021 vials of Gendicine for the third quarter of 2008, compared with 2,439 vials for the same quarter last year.”
To read the entire article visit http://www.beaconequity.com/m – Click on News and Commentary
Join the fastest growing investor community at: http://www.stockhideout.com/
BeaconEquity.comÂ’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting:
http://www.beaconequity.com/m
BeaconEquity.com is one of the industryÂ’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.beaconequity.com/m
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
Beacon Equity
Jeff Bishop
(469)-252-3505
press@beaconequity.com 
Source: EmailWire.com
|
|
|
|
